-The Hindu Company releases fact sheet detailing possible adverse events and those who are eligible for the Vaccine Those with any history of allergies, fever and bleeding disorder, on blood thinners and who are immunity compromised or on medication have been told by COVAXIN manufacturer Bharat Biotech not to take the Vaccine. A statement uploaded on the company website on Monday said the Vaccine was also contraindicated for pregnant/lactating women, those using other...
More »SEARCH RESULT
Total Matching Records found : 516
India's real GDP to expand by 10.1% in FY2022: Icra
-Livemint.com/ PTI Icra expects the headline CPI inflation to decline to 4.6% in FY2022 from 6.4% in FY2021, while exceeding the mid-point of the Monetary Policy Committee's medium target of 4%, for the third consecutive year MUMBAI: Domestic rating agency Icra Ratings on Monday said it expects the country's real gross domestic product (GDP) to grow by 10.1% in FY2022. It, however, said the value of GDP in the next financial year will...
More »Chhattisgarh says no to the use of Covaxin till clinical trial processes accomplished -Ejaz Kaiser
-The New Indian Express The state health minister T S Singh Deo said that it is "Not Safe" to use any Vaccine, which remains in clinical trial mode. RAIPUR: Congress-ruled Chhattisgarh government has categorically declared that it is not in favour of using indigenous Covid19-Covaxin in the vaccination process in the state unless it has completed the recommended testing process with absolute authentication and success. The state health minister T S Singh Deo...
More »Healthcare: 5 Non-COVID Areas To Focus On In 2021 -Anoo Bhuyan
-IndiaSpend.com Many health issues were neglected as COVID-19 hogged global attention in 2020. Apart from the COVID-19 Vaccine, what other health issues should be in focus in 2021? New Delhi: COVID-19 demanded the single-minded focus of India's entire healthcare infrastructure all through 2020. In fact, the pandemic hogged so much attention across all aspects of our lives that most other issues of public health were put on the back-burner. Issues such as tackling...
More »Experts raise questions over ‘hasty’ approval for COVID-19 Vaccines -Jacob Koshy
-The Hindu They advise against Covaxin, say there is no proof of efficacy. Several experts have raised concern over the “hasty approval” granted to the COVID-19 Vaccines despite the lack of adequate efficacy data. The Central Drugs Standard Control Organisation on Sunday accorded approval for restricted emergency use of the Oxford COVID-19 Vaccine Covishield, manufactured by the Serum Institute of India (SII), and the indigenously developed Vaccine Covaxin of Bharat Biotech. “I’m completely unaware...
More »
